C2N developed this groundbreaking test based upon longtime GHR partner Dr. Randall Bateman’s initial discovery of how to measure amyloid proteins in blood, validating its results in a clinical trial of 686 patients. Earlier this year, GHR made a Program-Related Investment (PRI) in C2N to provide the resources necessary to develop and launch this innovation.
The test is a highly sensitive blood test using mass spectrometry and is performed in C2N’s CLIA-certified lab. While the test by itself cannot diagnose Alzheimer’s disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the evaluation process.
Joel B. Braunstein, MD, CEO of C2N says, “Our mission is to translate exceptional science into unique diagnostics that can help as many people as possible. This blood test introduces a new option for patients, families and the medical community that have eagerly awaited innovative tools to address Alzheimer’s troubling problems.”
GHR Foundation is partnering boldly with a consortium of government, industry, academic research and other philanthropists on a game-changing undertaking – the prevention of Alzheimer’s disease. Learn more here.